Viral Vectors and Plasmid DNA Manufacturing Industry Research Report 2024
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
According to APO Research, The global Viral Vectors and Plasmid DNA Manufacturing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors and Plasmid DNA Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vectors and Plasmid DNA Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors and Plasmid DNA Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Viral Vectors and Plasmid DNA Manufacturing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- BioReliance
- Cobra Biologics
- Oxford BioMedica
- UniQure
- FinVector
- MolMed
- MassBiologics
- Richter-Helm
- FUJIFILM Diosynth Biotechnologies
- Lonza
- Aldevron
- Eurogentec
- Cell and Gene Therapy Catapult
- Biovian
- Thermo Fisher Scientific (Brammer Bio)
- VGXI
- PlasmidFactory
- Plasmid DNA
- Viral Vectors
- Cancers
- Inherited Disorders
- Viral Infections
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors and Plasmid DNA Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vectors and Plasmid DNA Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors and Plasmid DNA Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Viral Vectors and Plasmid DNA Manufacturing by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Plasmid DNA
2.2.3 Viral Vectors
2.3 Viral Vectors and Plasmid DNA Manufacturing by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Cancers
2.3.3 Inherited Disorders
2.3.4 Viral Infections
2.3.5 Others
2.4 Assumptions and Limitations
3 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY TYPE
3.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Type (2019-2024)
3.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Type (2025-2030)
4 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY APPLICATION
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Application (2019-2024)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Perspective (2019-2030)
5.2 Global Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region
5.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Region (2019-2024)
5.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Region (2025-2030)
5.3 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
5.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
5.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers
5.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
5.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue
6.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2019-2024)
6.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Players (2019-2024)
6.2 Global Viral Vectors and Plasmid DNA Manufacturing Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing Head office and Area Served
6.4 Global Viral Vectors and Plasmid DNA Manufacturing Players, Product Type & Application
6.5 Global Viral Vectors and Plasmid DNA Manufacturing Players, Date of Enter into This Industry
6.6 Global Viral Vectors and Plasmid DNA Manufacturing Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
7.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
7.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
8.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
8.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
9.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
9.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
10.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
10.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
11.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
11.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 BioReliance
12.1.1 BioReliance Company Information
12.1.2 BioReliance Business Overview
12.1.3 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.1.5 BioReliance Recent Developments
12.2 Cobra Biologics
12.2.1 Cobra Biologics Company Information
12.2.2 Cobra Biologics Business Overview
12.2.3 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.2.5 Cobra Biologics Recent Developments
12.3 Oxford BioMedica
12.3.1 Oxford BioMedica Company Information
12.3.2 Oxford BioMedica Business Overview
12.3.3 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.3.5 Oxford BioMedica Recent Developments
12.4 UniQure
12.4.1 UniQure Company Information
12.4.2 UniQure Business Overview
12.4.3 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.4.5 UniQure Recent Developments
12.5 FinVector
12.5.1 FinVector Company Information
12.5.2 FinVector Business Overview
12.5.3 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.5.5 FinVector Recent Developments
12.6 MolMed
12.6.1 MolMed Company Information
12.6.2 MolMed Business Overview
12.6.3 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.6.5 MolMed Recent Developments
12.7 MassBiologics
12.7.1 MassBiologics Company Information
12.7.2 MassBiologics Business Overview
12.7.3 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.7.5 MassBiologics Recent Developments
12.8 Richter-Helm
12.8.1 Richter-Helm Company Information
12.8.2 Richter-Helm Business Overview
12.8.3 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.8.5 Richter-Helm Recent Developments
12.9 FUJIFILM Diosynth Biotechnologies
12.9.1 FUJIFILM Diosynth Biotechnologies Company Information
12.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
12.9.3 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
12.10 Lonza
12.10.1 Lonza Company Information
12.10.2 Lonza Business Overview
12.10.3 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.10.5 Lonza Recent Developments
12.11 Aldevron
12.11.1 Aldevron Company Information
12.11.2 Aldevron Business Overview
12.11.3 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.11.5 Aldevron Recent Developments
12.12 Eurogentec
12.12.1 Eurogentec Company Information
12.12.2 Eurogentec Business Overview
12.12.3 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.12.5 Eurogentec Recent Developments
12.13 Cell and Gene Therapy Catapult
12.13.1 Cell and Gene Therapy Catapult Company Information
12.13.2 Cell and Gene Therapy Catapult Business Overview
12.13.3 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.13.5 Cell and Gene Therapy Catapult Recent Developments
12.14 Biovian
12.14.1 Biovian Company Information
12.14.2 Biovian Business Overview
12.14.3 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.14.5 Biovian Recent Developments
12.15 Thermo Fisher Scientific (Brammer Bio)
12.15.1 Thermo Fisher Scientific (Brammer Bio) Company Information
12.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
12.15.3 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
12.16 VGXI
12.16.1 VGXI Company Information
12.16.2 VGXI Business Overview
12.16.3 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.16.5 VGXI Recent Developments
12.17 PlasmidFactory
12.17.1 PlasmidFactory Company Information
12.17.2 PlasmidFactory Business Overview
12.17.3 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.17.5 PlasmidFactory Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Viral Vectors and Plasmid DNA Manufacturing by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Plasmid DNA
2.2.3 Viral Vectors
2.3 Viral Vectors and Plasmid DNA Manufacturing by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Cancers
2.3.3 Inherited Disorders
2.3.4 Viral Infections
2.3.5 Others
2.4 Assumptions and Limitations
3 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY TYPE
3.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Type (2019-2024)
3.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Type (2025-2030)
4 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY APPLICATION
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Application (2019-2024)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Perspective (2019-2030)
5.2 Global Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region
5.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Region (2019-2024)
5.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Region (2025-2030)
5.3 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
5.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
5.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers
5.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
5.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue
6.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2019-2024)
6.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Players (2019-2024)
6.2 Global Viral Vectors and Plasmid DNA Manufacturing Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing Head office and Area Served
6.4 Global Viral Vectors and Plasmid DNA Manufacturing Players, Product Type & Application
6.5 Global Viral Vectors and Plasmid DNA Manufacturing Players, Date of Enter into This Industry
6.6 Global Viral Vectors and Plasmid DNA Manufacturing Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
7.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
7.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
8.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
8.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
9.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
9.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
10.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
10.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
11.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
11.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 BioReliance
12.1.1 BioReliance Company Information
12.1.2 BioReliance Business Overview
12.1.3 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.1.5 BioReliance Recent Developments
12.2 Cobra Biologics
12.2.1 Cobra Biologics Company Information
12.2.2 Cobra Biologics Business Overview
12.2.3 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.2.5 Cobra Biologics Recent Developments
12.3 Oxford BioMedica
12.3.1 Oxford BioMedica Company Information
12.3.2 Oxford BioMedica Business Overview
12.3.3 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.3.5 Oxford BioMedica Recent Developments
12.4 UniQure
12.4.1 UniQure Company Information
12.4.2 UniQure Business Overview
12.4.3 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.4.5 UniQure Recent Developments
12.5 FinVector
12.5.1 FinVector Company Information
12.5.2 FinVector Business Overview
12.5.3 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.5.5 FinVector Recent Developments
12.6 MolMed
12.6.1 MolMed Company Information
12.6.2 MolMed Business Overview
12.6.3 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.6.5 MolMed Recent Developments
12.7 MassBiologics
12.7.1 MassBiologics Company Information
12.7.2 MassBiologics Business Overview
12.7.3 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.7.5 MassBiologics Recent Developments
12.8 Richter-Helm
12.8.1 Richter-Helm Company Information
12.8.2 Richter-Helm Business Overview
12.8.3 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.8.5 Richter-Helm Recent Developments
12.9 FUJIFILM Diosynth Biotechnologies
12.9.1 FUJIFILM Diosynth Biotechnologies Company Information
12.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
12.9.3 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
12.10 Lonza
12.10.1 Lonza Company Information
12.10.2 Lonza Business Overview
12.10.3 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.10.5 Lonza Recent Developments
12.11 Aldevron
12.11.1 Aldevron Company Information
12.11.2 Aldevron Business Overview
12.11.3 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.11.5 Aldevron Recent Developments
12.12 Eurogentec
12.12.1 Eurogentec Company Information
12.12.2 Eurogentec Business Overview
12.12.3 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.12.5 Eurogentec Recent Developments
12.13 Cell and Gene Therapy Catapult
12.13.1 Cell and Gene Therapy Catapult Company Information
12.13.2 Cell and Gene Therapy Catapult Business Overview
12.13.3 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.13.5 Cell and Gene Therapy Catapult Recent Developments
12.14 Biovian
12.14.1 Biovian Company Information
12.14.2 Biovian Business Overview
12.14.3 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.14.5 Biovian Recent Developments
12.15 Thermo Fisher Scientific (Brammer Bio)
12.15.1 Thermo Fisher Scientific (Brammer Bio) Company Information
12.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
12.15.3 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
12.16 VGXI
12.16.1 VGXI Company Information
12.16.2 VGXI Business Overview
12.16.3 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.16.5 VGXI Recent Developments
12.17 PlasmidFactory
12.17.1 PlasmidFactory Company Information
12.17.2 PlasmidFactory Business Overview
12.17.3 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
12.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
12.17.5 PlasmidFactory Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
